Markets

Here’s Why The Medicines Company Jumped Higher Again Today

What happened

Shares of The Medicines Company (NASDAQ: MDCO) are up 18.6% at 12:19 p.m. EST after Bloomberg reported that the drugmaker had gotten interest from potential acquirers, including Novartis (NYSE: NVS).

So what

A potential suitor would be after The Medicines Company's cholesterol-lowering drug inclisiran, which posted solid phase 3 results this week. The company plans to file a marketing application with the Food and Drug Administration before the end of the year and then file in Europe at the beginning of next year.

The acquisition wouldn't come cheap. Even before today's move, The Medicines Company had tripled this year and now sits at a market cap over $5.5 billion. At five times sales, there's already $1 billion in sales baked into the drug.

Amgen's (NASDAQ: AMGN) Repatha, which has the same target as inclisiran, had a run rate of about $670 million based on third-quarter revenue. Sales of the drug are still growing -- they were up 40% year over year in the most recent quarter -- so hitting $1 billion with inclisiran doesn't seem too far-fetched.

A larger company like Novartis would have a much easier time competing with Amgen, as well as Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals (NASDAQ: REGN), which sell a drug called Praluent that's also in the same class of drugs.

Arms in business suits shaking hands

Image source: Getty Images.

Now what

The rumor that Novartis is interested in buying The Medicines Company is likely true, but that doesn't mean that a deal will definitely get done; the companies still have to agree to a price.

In fact, one side feeling the need to leak the rumor of the potential deal to the media could be a sign that the two sides are far from reaching a compromise.

Without any inside knowledge, biotech investors should proceed with caution at this buoyed price.

10 stocks we like better than The Medicines Company
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and The Medicines Company wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of June 1, 2019

 

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MDCO SNY AMGN REGN NVS

Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More